Literature DB >> 11259030

Convenient synthesis and diversification of dehydroalaninyl phosphinic peptide analogues.

M Matziari1, D Georgiadis, V Dive, A Yiotakis.   

Abstract

[structure: see text]. Dehydroalaninyl phosphinic dipeptide analogues were synthesized, via an efficient tandem Arbuzov addition/allylic rearrangement, in high yields. The susceptibility of the conjugate system to 1,4 nucleophilic additions was investigated. C-Elongation of the dipeptides was performed, and the efficiency of 1,4 addition to the resulting acrylamidic moiety was evaluated. Derivatization of such phosphinic templates is a powerful approach for rapid access to large number of phosphinic pseudopeptides bearing various side chains in the P1' position.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259030     DOI: 10.1021/ol0069103

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  4 in total

1.  Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors.

Authors:  Janelle Lauer-Fields; Keith Brew; John K Whitehead; Shunzi Li; Robert P Hammer; Gregg B Fields
Journal:  J Am Chem Soc       Date:  2007-08-02       Impact factor: 15.419

2.  Borane Complexes of the H(3)PO(2) P(III) Tautomer: Useful Phosphinate Equivalents.

Authors:  Yamina Belabassi; Monika I Antczak; Jennifer Tellez; Jean-Luc Montchamp
Journal:  Tetrahedron       Date:  2008-09-22       Impact factor: 2.457

3.  Structure-guided, single-point modifications in the phosphinic dipeptide structure yield highly potent and selective inhibitors of neutral aminopeptidases.

Authors:  Stamatia Vassiliou; Ewelina Węglarz-Tomczak; Łukasz Berlicki; Małgorzata Pawełczak; Bogusław Nocek; Rory Mulligan; Andrzej Joachimiak; Artur Mucha
Journal:  J Med Chem       Date:  2014-09-22       Impact factor: 7.446

Review 4.  Synthesis and modifications of phosphinic dipeptide analogues.

Authors:  Artur Mucha
Journal:  Molecules       Date:  2012-11-15       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.